Galvus (Novartis) fails German G-BA review for Diabetes

Galvus (vildagliptin) from Novartis offers no extra benefit over generic sulfonylureas, according to the G-BA, the body in charge of Germany's pricing and reimbursement process, following a recommendation by IQWiG. The decision, part of first ever retrospective assessment could lead to a big price cut for Galvus to the level of generic sulfonylureas, or withdrawal from the market.

Januvia (sitagliptin) and Onglyza (saxagliptin) offered a "hint" of a "minor" additional benefit but not a "proven" benefit. Tradjenta (linagliptin) in the recent past also failed the review twice and was not launched in Germany.The G-BA review lasts 2 years and ongoing longer term studies may offer new evidence to support a further review.